FORCE Blog

This blog will cover topics of interest that affect our community. Unless otherwise stated, the blog articles will be written by Sue Friedman, Executive Director of FORCE.

| More

Posts Tagged ‘brca research’

November 14, 2016

Voices of FORCE: A BRCA Mutation is a Factor in Pancreatic Cancer

By Rona Greenberg Hereditary breast and ovarian cancer is part of my family history. My grandmother, Rebecca, for whom I am named, died from breast/ovarian cancer in1934; my mother was ten years old. My mother died from the same cancer in 1967; I was nineteen years old with three younger sisters. In 1997, I was … + read more

November 1, 2016

Learn About Hereditary Pancreatic Cancer

by Lisa Rezende, PhD November is Pancreatic Cancer Awareness Month. FORCE wants to raise awareness of the risk of pancreatic cancer in the hereditary cancer community. Pancreatic cancer is rare but BRCA carriers have a high risk, up to 5% compared to the 1.5% for the general population. Between BRCA carriers, the risk is higher … + read more

September 30, 2016

HBOC Week Special: Inherited Mutations in BRCA1/2 and Related Genes More Common Than Expected in Men with Advanced Prostate Cancer

Guest blog by Heather H. Cheng, MD, PhD Researchers have long been aware that prostate cancer carries a substantial familial risk. New data (Robinson, et al Cell 2015) from the Stand Up To Cancer-Prostate Cancer Foundation International Dream Team collaborative group examined the genetic sequence of 150 tumors from men with advanced, hormone-resistant, metastatic prostate … + read more

July 28, 2016

Metastatic Hereditary Breast Cancer Treatment Research: BROCADE 3 Study

By Heather Han, MD and Sue Friedman Metastatic Hereditary Breast Cancer Research There are major gaps in research, resources, and support for people with metastatic breast cancer – cancer that has spread beyond the breast and lymph nodes. A promising area of research is focusing on new treatments for hereditary metastatic breast cancer caused by … + read more

June 2, 2016

Results from the KNOW MORE Survey: Genetic Counseling and Testing in Women with Different Types of Ovarian Cancer

KNOW MORE is a campaign designed by FORCE to help women diagnosed with ovarian, fallopian tube, or primary peritoneal cancers make informed decisions about genetic counseling and testing for inherited gene mutations. We kicked off the effort by launching a brief survey to better understand how women with ovarian and related cancers make decisions about genetic … + read more

May 27, 2016

Blog: What Do the New Guidelines from the National Comprehensive Cancer Network Mean For You?

by Lisa Rezende, PhD People with hereditary cancer face many decisions, such as whether or not to have genetic testing, choosing the best type and frequency of cancer screening, and whether or not to manage cancer risk through surgery. Health care providers look to national guidelines to give their patients advice as they make these … + read more

May 19, 2016

Updates in Research on Treating Hereditary Cancers

Note: This post which was originally published 08/4/15 was just updated on 05/19/16. In December 2014, the FDA approved the first targeted therapy for people with BRCA mutations. Lynparza, a type of medication known as a PARP inhibitor, was approved for women with a BRCA mutation to treat advanced ovarian, fallopian tube, or primary peritoneal cancer that has progressed after … + read more

May 10, 2016

Experience with Oncology Clinical Trial Participation and Impact on Future Trial Design and Conduct

Note: Last year, TESARO, a pharmaceutical company developing a new PARP inhibitor for treatment of ovarian cancer and metastatic breast cancer, asked FORCE to help recruit previous clinical trial participants to join focus groups across the U.S. TESARO wanted to understand the patient experience to build clinical trials that are more responsive to patient needs. We … + read more

March 30, 2016

Update on Pancreatic Cancer Genetics Research

By Talia Golan, MD and Sue Friedman, DVM BRCA and pancreatic cancer The link between breast and ovarian cancer and BRCA mutations has been known since the 1990s. However, the awareness that these mutations also increase pancreatic cancer risk is more recent. If all patients with pancreatic cancer were tested for a BRCA1 or BRCA2 … + read more

March 17, 2016

Ovarian Cancer Survivors with a Negative Genetic Test Result in the Past May Benefit from Additional Genetic Counseling/Testing

KNOW MORE is a new campaign designed by FORCE to inform every woman diagnosed with ovarian, fallopian tube, and primary peritoneal cancer about national guidelines on genetic counseling and testing for inherited gene mutations. We kicked off the campaign by launching a brief survey to better understand how women with ovarian cancer make decisions around … + read more

March 3, 2016

OlympiA: A Landmark Breast Cancer PARP Inhibitor Clinical Trial

by Sue Friedman Great progress has been made since the identification of the BRCA1 and BRCA2 genes and their link to causing breast, ovarian, pancreatic and other cancers. Over the last two decades, researchers have studied how BRCA mutations cause cancer in an effort to develop new treatments. In December 2014, Lynparza, (olaparib), a type … + read more

January 8, 2016

Value in Cancer Care: Including Consumers in the Dialogue

by Lisa Schlager, Vice President of Policy and Community Affairs Value and access to appropriate health care is of vital importance to patients and their families, particularly as cancer diagnoses continue to rise—up more than 20 percent in the past decade—and health care costs steadily increase. In this environment, more attention is being paid to … + read more

September 27, 2015

Beyond Awareness: Working to Improve Outcomes for People Facing Hereditary Cancer

This week we mark National Hereditary Breast and Ovarian Cancer (HBOC) Week, and on Wednesday, National Previvor Day. This awareness campaign acknowledges the over one million people and families in the United States affected by hereditary cancer, due to a BRCA, PALB2, PTEN, ATM or other mutation linked to these cancers or a strong family history … + read more

September 5, 2015

Proposed Regulatory Changes Will Undermine Patient Protections Under GINA

Employees will be faced with a difficult choice—either disclose personal health information or maintain their privacy and pay more for health coverage. by Lisa Schlager Personal privacy and workplace protections are in jeopardy with recent proposals by the Equal Employment Opportunity Commission (EEOC). In April, the Commission proposed revising and reinterpreting the Americans with Disabilities Act (ADA) … + read more

September 3, 2015

Guest Blog: We All Deserve the Chance to Make Decisions About Our Futures

By Teri Woodhull Like most families in the FORCE community, cancer followed my family for generations. Breast cancer touched my mother, her mother, her mother’s mother, and my mother’s first cousin. And me. We knew it had to be more than a coincidence. My mother died at 46 of breast cancer. Her oncologist and other … + read more

Connect with others.

Call our Helpline

Our helpline offers peer support for people concerned about hereditary cancer. All calls are confidential. Call any time.

Join a Local Group

FORCE has outreach groups throughout the United States and in Essex, United Kingdom that meet periodically to offer peer support, and share resources.

FORCE:Facing Our Risk of Cancer Empowered